Figure 4.

Proportion of responders at each visit (subjects with a ≥1-grade FWS improvement from baseline at maximum frown), assessed by investigator (secondary endpoint, mITT population^a). ^aAll randomized and treated subjects with a baseline and at least 1 postbaseline efficacy assessment, only in the DB phase. *P < 0.05 vs onabotulinumtoxinA 20 U by the Cochran-Mantel-Haenszel test stratified by center. ^§Primary time point. DB, double-blind; FWS, Facial Wrinkle Scale; mITT, modified intent-to-treat.